Disufenton sodium
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Disufenton sodium (Cerovive, OKN-007, NXY-059, HPN-07)[1] is a free radical trapping nitrone-based antioxidant compound that has been under development for several medical conditions.[2][3]
Chemistry
Disufenton sodium is the disulfonyl derivative of the neuroprotective nitrone spin trap phenylbutylnitrone or "PBN". PBN and its derivatives hydrolyze and oxidize in vitro to form respectively MNP-OH (AKA, NtBHA) and its parent spin-trap MNP.
Research
Disufenton sodium was under development at the drug company AstraZeneca. A 2005 phase-3 clinical trial[4][5] called "SAINT-1" reported some efficacy in the acute treatment of ischemia injury due to stroke. However, a 2006 attempt to repeat this trial indicated no significant activity. After ruling out other causes, the authors tentatively attributed the positive results in the first trial to "chance".[4] AstraZeneca then terminated the development programme.[6]
Disufenton sodium has been researched as a potential treatment for use in brain tumors and cancers, including
A compound (NHPN-1010) containing a combination of disufenton sodium and acetylcysteine has been researched as a potential treatment for tinnitus and hearing loss.[11][12][13][14]
References
- PMID 34539349.
- S2CID 36633423.
- PMID 26771008.
- ^ PMID 16467546.
- PMID 17068304.
- ^ "Renovis: Press Release". Archived from the original on October 28, 2006.
- PMID 33168005.
- ^ "FDA grants fast track status to OKN-007 for diffuse intrinsic pontine glioma". Healio. March 3, 2021. Retrieved February 5, 2022.
- S2CID 219772612.
- PMID 34910361.
- PMID 33411811.
- S2CID 208621727.
- ^ "Congressionally Directed Medical Research Programs (CDMRP) Search Awards". Congressionally Directed Medical Research Programs. Retrieved February 5, 2022.
- ^ Martin B (July 27, 2020). "Hough Ear Institute receives $300K grant to support research treatments for hearing loss". KOKH. Retrieved February 5, 2022.
Further reading
- Fong JJ, Rhoney DH (March 2006). "NXY-059: review of neuroprotective potential for acute stroke". The Annals of Pharmacotherapy. 40 (3): 461–471. S2CID 38016035.
- Warner DS, Sheng H, Batinić-Haberle I (August 2004). "Oxidants, antioxidants and the ischemic brain". The Journal of Experimental Biology. 207 (Pt 18): 3221–3231. S2CID 15392635.